Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
about
Current status and evolution of preclinical drug development models of epithelial ovarian cancerVascular endothelial growth factor as an anti-angiogenic target for cancer therapyBevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.Phage display peptide probes for imaging early response to bevacizumab treatment.Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers.TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models.Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.The merits of vascular targeting for gynecologic malignancies.Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesVascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Novel agents in epithelial ovarian cancer.Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancerImproving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancerOvarian cancer metastasis: integrating insights from disparate model organisms.Angiogenesis in normal and neoplastic ovaries.Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer.Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.Anti-VEGF therapy: a new approach to colorectal cancer therapy.Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.Challenges for patient selection with VEGF inhibitors.The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusionAngiogenesis-related pathways in the pathogenesis of ovarian cancerMining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsMolecular targeted therapy in ovarian cancer: what is on the horizon?Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.Molecular-targeted therapies for ovarian cancer: prospects for the future.Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
P2860
Q27028117-C1468612-C6E9-4B6A-81E1-BBB55DDEB8DEQ30455612-B1E448EE-9595-44B1-AC6A-54EC533E95E7Q33404538-37F3167E-4D16-4430-B130-D9EF48D769A5Q33541076-2F00EE4D-3971-4155-A4CA-68A4EEC9CD2FQ33771212-4353D669-39C7-42AF-BF5C-0E99828958B7Q34516315-7F62BE44-D2FE-4A18-A2A3-6BD6FF3252F3Q34694524-E65EBD9B-B9CE-4ABA-925E-089FB5956750Q35094484-43B94B11-B4D8-4420-9B96-B6C89DB08318Q35116734-3840A892-0CD5-4263-82AA-30FCC1A12264Q35163538-0AF5DEF7-C367-4041-B1E6-F1FD75314BF3Q35233993-91F1A173-5F18-478F-B5AC-146A8C73F5B9Q35652113-3ED6F915-6946-424E-A9AF-DAD72E978038Q35750289-1EA02179-5B96-4907-BEB7-8CB629BD7F63Q35954103-E7A416CE-C75F-4A29-B2AB-036F8811F73CQ35968752-346E0EAE-4AA4-4E31-90CE-6BE3966F6B2DQ35995186-7E06970F-4921-461B-8A9B-41D8B1CCB5CFQ36064914-26DF50CC-BAEA-4745-AC9E-2B06C848DB79Q36089989-4C0045B7-8C9E-4E73-9C33-9A35CFBDF5A8Q36104744-873AA21F-2D49-428E-9FD1-CEE66E7B22F8Q36111930-28E67D31-82BC-43BE-8420-0AC91C70DA0DQ36279903-7DE66D58-F82C-471A-88EB-4B12FCE521D6Q36343773-9F1A4B2D-FFEE-49C0-B38A-872478203F1EQ36430273-DD76F52A-5DCB-4C81-8359-9CCC8D75F8E4Q36508627-54F6FDFD-77CC-4BE6-904F-E5E114D2C866Q36557500-E184568B-5ECB-4AB1-96AA-E1277F517496Q36636633-4B528FFE-9996-451B-BCE6-8F8A6BC02443Q36658018-5852D839-A837-4484-B30D-99A4649F66E8Q36763649-872D4760-316E-4B9E-988F-A48F9305794CQ36907325-B1B8A329-E23D-47D5-AA3B-4120B3E794EFQ37139109-158C3A62-F8BE-4A22-B11C-E3740B44147BQ37154428-F03A43EC-E59B-4D05-9C81-A2A95F3F62FEQ37168526-0FD461F1-612D-4FFF-9CF2-8EB7EEEC7125Q37447340-43515286-FA77-4D9A-9ED2-B46BEF192DA0Q37888659-24B1AA88-E320-4C84-B3CC-9CE2E4E4517AQ38003707-2995C547-EBD6-4BDE-9918-B63C79A01506Q38036942-6DD028DD-A8AF-4BA7-8BBE-2D78381AD117Q38040628-82350918-917A-4BA9-ABDC-8862D25C7A29Q38066339-15E21066-C704-4323-837F-3F3054DA9C3CQ38111265-65517E0C-0311-4BF7-81D2-54598834F21AQ38171330-B55BA39D-BFD4-4EA3-8A06-FF90D5547A35
P2860
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Vascular endothelial growth fa ...... mouse model of ovarian cancer
@ast
Vascular endothelial growth fa ...... mouse model of ovarian cancer
@en
type
label
Vascular endothelial growth fa ...... mouse model of ovarian cancer
@ast
Vascular endothelial growth fa ...... mouse model of ovarian cancer
@en
prefLabel
Vascular endothelial growth fa ...... mouse model of ovarian cancer
@ast
Vascular endothelial growth fa ...... mouse model of ovarian cancer
@en
P2093
P2860
P1476
Vascular endothelial growth fa ...... mouse model of ovarian cancer
@en
P2093
Charles Zaloudek
Judith Hofmann
Napoleone Ferrara
Robert B Jaffe
Thomas Hamilton
P2860
P304
P356
10.1016/S0002-9440(10)64467-7
P407
P577
2002-11-01T00:00:00Z